Yvette van der linden

Prof. Dr. Yvette van der linden

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2005 in Cancer
Verified
Journal Article
Closed access
PDF file
YLYvette van der linden
Yvette van der linden
YMYvette M.
Yvette M.
SDSander P. D. S. Dijkstra
Sander P. D. S. Dijkstra
EVErnest J. A. Vonk
Ernest J. A. Vonk
CMCorrie A. M. Marijnen
Corrie A. M. Marijnen
JLJan Willem H. Leer
Jan Willem H. Leer

1 April 2012 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
ECEdward Chow
Edward Chow
PHPeter Hoskin
Peter Hoskin
GMGunita Mitera
Gunita Mitera
LZLiang Zeng
Liang Zeng
SLStephen Lutz
Stephen Lutz
EKEshwar Kumar
Eshwar Kumar

1 June 2004 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
YLYvette van der linden
Yvette van der linden
JLJudith J Lok
Judith J Lok
ESElsbeth Steenland
Elsbeth Steenland
HMHendrik Martijn
Hendrik Martijn
HHHans van Houwelingen
Hans van Houwelingen
JLJan Willem H Leer
Jan Willem H Leer

5 February 2003 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
WHWilbert B Van Den Hout
Wilbert B Van Den Hout
YLYvette van der linden
Yvette van der linden
ESElsbeth Steenland
Elsbeth Steenland
RWRuud G J Wiggenraad
Ruud G J Wiggenraad
JKJob Kievit
Job Kievit
JLJan Willem H Leer
Jan Willem H Leer
Background: Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases. Although single- and multiple-fraction radiotherapy are thought to provide equal palliation, which treatment schedule provides better value for the money is unknown. We compared quality-adjusted life expectancy (the overall valuation of the health of the patients) and societal costs for patients receiving either single- or multiple-fraction radiotherapy. Methods: A societal cost–utility analysis was performed on a Dutch randomized, controlled trial of 1157 patients with painful bone metastases that compared pain responses and quality of life from a single-fraction treatment schedule of 8 Gy with a treatment schedule of six fractions of 4 Gy each. The societal values of life expectancies were assessed with the EuroQol classification system (EQ-5D) questionnaire. A subset of 166 patients also answered additional questionnaires to estimate nonradiotherapy and nonmedical costs. Statistical tests were two-sided. Results: Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P = .20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P = .21). The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001). The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule, but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = –$99 to $3604; P = .06). For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P≤.05). Conclusions: Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands. Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.

1 September 2012 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
MHMerel Huisman
Merel Huisman
MBMaurice A.A.J. van Den Bosch
Maurice A.A.J. van Den Bosch
JWJoost W. Wijlemans
Joost W. Wijlemans
MVMarco van Vulpen
Marco van Vulpen
YLYvette van der linden
Yvette van der linden
HVHelena M. Verkooijen
Helena M. Verkooijen

1 March 2006 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
YLYvette van der linden
Yvette van der linden
ESElsbeth Steenland
Elsbeth Steenland
HHHans C. van Houwelingen
Hans C. van Houwelingen
WPWendy J. Post
Wendy J. Post
BOBing Oei
Bing Oei
JLJan Willem H. Leer
Jan Willem H. Leer